...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Posttherapeutic cure criteria in chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests
【24h】

Posttherapeutic cure criteria in chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests

机译:Posttherapeutic治愈标准恰加斯病的疾病:传统的血清学补充紧随其后血清学、寄生虫学的和分子测试

获取原文
获取原文并翻译 | 示例
           

摘要

We performed a critical study of conventional serology, followed by supplementary serological, parasitological, and molecular tests, to assess the response to etiologic treatment of Chagas' disease. A group of 94 Chagas' disease patients treated with benznidazole at least 10 years earlier were evaluated from the laboratory and clinical points of view. When conventional serology (enzyme- linked immunosorbent assay [ELISA], indirect immunofluorescence [IIF], and indirect hemagglutination [IHA]) and classic criteria (consistent results with any two of the three tests) or more rigorous criteria (consistent results from the three tests) were used, 10.6% and 8.5% of patients were considered treated and cured (TC) by classic and rigorous criteria, respectively. Patients were then evaluated using supplementary (recombinant ELISA and Trypanosoma cruzi excreted-secreted antigen blotting [TESA-blot]), parasitological (hemoculture), and molecular (PCR) tests. The results of recombinant ELISA were similar to those with the rigorous criterion (three consistent test results). The TESA-blot group showed a higher percentage (21.3%) of negative results than the groups defined by either cure criterion. Hemoculture and PCR gave negative results for all treated and cured (TC) patients, regardless of the criterion used. Recombinant ELISA and TESA-blot tests showed negative results for 70% and 87.5% of the patients categorized as TC by the classic and three-test criteria, respectively. For patients with discordant conventional serology, the supplementary serological and molecular tests were the decisive factor in determining therapeutic failure. Clinical evaluation showed that 62.5% of TC patients presented with the indeterminate form of the disease. Additionally, treated patients with negative TESA-blot results should be reevaluated later with all methodologies used here to verify whether TESAblot is a reliable way to determine early parasitological cure of Chagas' disease.
机译:我们扮演了一个关键的研究传统血清学,紧随其后的是补充血清,寄生虫学的,和分子测试,来评估恰加斯病的病原学的治疗反应疾病。使用苄硝唑治疗至少10年从实验室和早些时候进行评估临床的观点。血清学(酶联免疫吸附测定(ELISA),间接免疫荧光法(IIF)间接血凝(IHA))和经典标准(与任何的两个一致的结果三个测试)或更严格的标准(从三个测试一致的结果)使用,10.6%和8.5%的患者被认为是治疗和治愈(TC)经典的和严格的标准,分别。评估使用补充(重组ELISA和鲁兹锥体excreted-secreted抗原印迹[TESA-blot]),寄生虫学的(血培养),分子(PCR)测试。重组ELISA结果是相似的(三个严格的标准一致的测试结果)。显示比例较高(21.3%)的负面的结果比定义的群体治疗标准。结果所有病人治疗或治愈(TC),无论所使用的标准。ELISA和TESA-blot测试显示负面结果70%和87.5%的患者分为TC的经典和三个测试标准,分别。传统的血清学,补充血清学和分子检测是决定性的因素在决定治疗失败。临床评估显示,62.5%的TC病人的不定式这种疾病。负TESA-blot结果应该评估后来这里使用所有的方法来验证TESAblot是不是一个可靠的方法来确定南美洲锥虫病的寄生虫学的早期治疗。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号